Among three patients with melanoma receiving anti–PD-1 antibodies, the use of checkpoint blockers led to the development of serious autoimmune pneumonitis, a potentially lethal complication.
CITATION STYLE
Nishino, M., Sholl, L. M., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2015). Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy. New England Journal of Medicine, 373(3), 288–290. https://doi.org/10.1056/nejmc1505197
Mendeley helps you to discover research relevant for your work.